Irinotecan and Anlotinib for Epithelioid Sarcoma
Not Applicable
Withdrawn
- Conditions
- Objective ResponseOverall Survival
- Interventions
- Drug: VIA combination treatment
- Registration Number
- NCT05656222
- Lead Sponsor
- Peking University People's Hospital
- Brief Summary
Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1/INI1 deficiency. Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other systemic treatments are generally ignored. To explore alternative treatment options, we studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- (1) Grade 2 or 3 ES confirmed histologically using the American Joint Committee on Cancer (AJCC) system ;
- (2) patients presented with measurable lesions using the Response Evaluation Criteria In Solid Tumors (RECIST1.1) and were not amenable to surgical resection or radiotherapy;
- (3) primary or secondary metastatic disease;
- (4) received more than two courses of the VIA regimen;
- (5) no concurrent treatment was given while on the VIA regimen;
- (6) follow-up information and evaluation after chemotherapy were available.
Exclusion Criteria
- less than 4 cycles of treatment;
- medical records were not complete.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description VIA treatment Group VIA combination treatment -
- Primary Outcome Measures
Name Time Method Objective Response Rate 12 weeks Based on RECIST1.1 criteria, clinical evaluation was done once every 6 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Peking University People's Hospital
🇨🇳Beijing, China